Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen

Yoshihiro Hirata, Takako Serizawa, Satoki Shichijo, Nobumi Suzuki, Kosuke Sakitani, Yoku Hayakawa, Atsuo Yamada, Kazuhiko Koike

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Objective To examine the efficacy of third-line Helicobacter pylori eradication therapy with esomeprazole, amoxicillin, and sitafloxacin for patients with clarithromycin- and metronidazole-based first- and second-line therapy failure. Methods Thirty patients with first- and second-line H. pylori eradication failure were treated prospectively with esomeprazole 20 mg twice daily, amoxicillin 750 mg twice daily, and sitafloxacin 100 mg twice daily for 7 days. After 8–12 weeks, the outcome of eradication therapy was assessed by 13C-urea breath test or stool antigen test. Results All 30 patients completed the study. Eradication was successful in 25 patients and the eradication rate was 83% in the intention-to-treat and per-protocol analyses. No specific or significant adverse events were recorded in the 30 patients. Patient characteristics such as sex, body mass index, and pepsinogen I/II ratio did not differ between patients who were treated successfully and those who were not treated successfully. Conclusions Third-line H. pylori eradication therapy with esomeprazole, amoxicillin, and sitafloxacin is as safe and effective as previously reported sitafloxacin-based triple therapy.

Original languageEnglish
Pages (from-to)66-69
Number of pages4
JournalInternational Journal of Infectious Diseases
Publication statusPublished or Issued - 1 Oct 2016
Externally publishedYes


  • Esomeprazole
  • Helicobacter pylori
  • Sitafloxacin
  • Third-line eradication

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this